The product is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Also known as blood coagulation factor XIV. The product is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot formation. The product pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli. A lack of blood coagulation factor XIV in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation with thrombosis. The product is available in concentrated form as the product Ceptrotin, which is indicated foruse in pediatric and adult patients with severe congenital deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.	Human protein C	
https://www.creativebiomart.net/therapeutic-proteins/p/17/endogenously-occurring-plasma-protein-and-blood-coagulation-factor-xiv/

Human protein C

323 views
0

The product is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Also known as blood coagulation factor XIV. The product is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot formation. The product pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli. A lack of blood coagulation factor XIV in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation with thrombosis. The product is available in concentrated form as the product Ceptrotin, which is indicated foruse in pediatric and adult patients with severe congenital deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. Human protein C
https://www.creativebiomart.net/therapeutic-proteins/p/17/endogenously-occurring-plasma-protein-and-blood-coagulation-factor-xiv/

Uploaded to 3 years ago

In this album

Proudly hosting 6067655 Images.

We'll be back soon!

Sell from your existing website with Shoprocket